盐酸齐拉西酮和氟哌啶醇对精神分裂症认知灵活性的疗效比较

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (12): 1410-1413.

盐酸齐拉西酮和氟哌啶醇对精神分裂症认知灵活性的疗效比较

季卫东^1,2,3, 杨道良^1,2, 郭田友³, 杨闯³, 周家秀³, 姚静³, 黄晓琦³

1上海市长宁精神卫生中心, 上海 200335;
²上海交通大学精神神经科学和系统代谢组学研究所, 上海 200335;
³四川大学华西医院心理卫生中心, 成都 610041, 四川

收稿日期:2009-09-26 修回日期:2009-11-05 发布日期:2020-10-20
作者简介:季卫东, 男, 博士, 主任医师, 研究方向:分子精神药理学。Tel:021-52194388 　E-mai l:jidong1999@126.com

Effect of ziprasidone hydrochloride and haloperidol on cognitive flexibility in schizophrenia

JI Wei-dong^1,2,3, YANG Dao-liang^1,2, GUO Tian-you³, YANG Chuang³, ZHOU Jia-xiu³, YAO Jing³, HUANG Xiao-qi³

¹Shanghai Changning Mental Health Center, Shanghai Jiao Tong University, Shanghai 200335, China;
²Institute of Neuropsychiatric Science and Systems BiologicalMedicine,Shanghai Jiao Tong University, Shanghai 200335, China;
³Mental Health Center of Huaxi Hospital of Sichuan University, Chengdu 610041, Sichuang, China

Received:2009-09-26 Revised:2009-11-05 Published:2020-10-20

摘要/Abstract

摘要： 目的：探讨比较盐酸齐拉西酮和氟哌啶醇对精神分裂症患者认知灵活性的疗效。方法：对50 例服用齐拉西酮维持治疗与50 例服用氟哌啶醇维持治疗的精神分裂症患者进行12 个月随访,采用威斯康星卡片分类(WCST)和连线测验(Trailing Making)评估患者的认知灵活性。结果：维持治疗12 个月末齐拉西酮组和氟哌啶醇组的WCST 测验中的总分类次数、错误数、持续错误数、非持续错误数以及连线测验各指标(连线A 、B时间,A 、B 错误数和A 、B 犯规数)均显著下降(P<0.05), 并且齐拉西酮组的持续错误数减分率显著高于氟哌啶醇组(P <0.05)。治疗后, 两组连线测验成绩减分率差异无统计学意义(P >0.05)。结论：齐拉西酮较氟哌啶醇更有益于改善精神分裂症患者的认知灵活性。

关键词: 齐拉西酮, 氟哌啶醇, 精神分裂症, 认知灵活性

Abstract: AIM: To explore the long-time efficacy of ziprasidone hydrochloride in the treatment of cognitive flexibility in schizophrenia.METHODS: 50 cases of patients continuously treated with ziprasidone hydrochloride and 50 cases of patients treated with haloperidol were included in the 12 months follow-up study. Cognitive flexibility was tested with Wisconsin card sorting test (WCST) and Trail Making Test.RESULTS: At the time of 12 months, all the scores of total trial, sorts, perseverative errors and random errors on WCST and all target of Trail Making Test were significantly decreased in the two groups of patients (P < 0.05 or P <0.01);but the decreased rate of perseverative errors on WCST of ziprasidone hydrochloride group were significantly higher than that of Haloperidol group(P <0.01).CONCLUSION: Compare with Haloperidol, ziprasidone hydrochloride has a better efficacy in the long-time treatment of cognitive flexibility in schizophrenia.

Key words: ziprasidone hydrochloride, haloperidol, schizophrenia, cognitive flexibility

中图分类号:

R964

季卫东, 杨道良, 郭田友, 杨闯, 周家秀, 姚静, 黄晓琦. 盐酸齐拉西酮和氟哌啶醇对精神分裂症认知灵活性的疗效比较[J]. 中国临床药理学与治疗学, 2009, 14(12): 1410-1413.

JI Wei-dong, YANG Dao-liang, GUO Tian-you, YANG Chuang, ZHOU Jia-xiu, YAO Jing, HUANG Xiao-qi. Effect of ziprasidone hydrochloride and haloperidol on cognitive flexibility in schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1410-1413.

参考文献

[1] Harvey PD, Meltzer H, Simpson GM, et al.Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia[J].Schizophr Res, 2004, 66(2 3):101-113.
[2] Paulsen JS, Salmon DP, Monsch AU, et al.Discrimination of cortical from subcortical dementias on the basis of memory and problem-solving[J].J Clin Psychol, 1995, 51(1):48-51.
[3] Lu L, Bigler ED.Performance on original and a Chineseversion of Trail Making Test Part B:A normative bilingual sample[J].J Appl Neuropsy-chology, 2000, 7(1):243-246.
[4] Smith EE, Jonides J.Storage and executive processes in the frontal lobes[J].Science, 1999, 283(11):1657-1661.
[5] Neuhaus AH, Opgen-Rhein C, Urbanek C, et al.COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia[J].Pharmacopsychiatry, 2009, 42(4):141-144.
[6] Gibel A, Ritsner MS.Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care:a 12-month, open-label, flexibledose, naturalistic observational trial[J].Clin Neuropharmacol, 2008, 31(4):204-220.
[7] Daban C, Amado I, BourdelMC, et al.Cognitive dysfunctions in medicated and unmedicated patients with recentonset schizophrenia[J].J Psychiatr Res, 2005, 39(2): 391-398.
[8] Woodward ND, Purdon SE, Meltzer HY, et al.A metaanalysis of neuropsychological change to clozapine, quetiapine and risperidone in schizophrenia[J].Int J Neuropsychopharmacol, 2005, 8(4):457-472.
[9] Tonmoy S.Cognitive effects of conventional and atypicalantipsychotics in schizophrenia[J].Br J Psychiatry, 1999, 174(Suppl 38):44-51.
[10] Weiser M, Shneider Beer M.Improment in cognition associated with novel antipsychotic drugs:a direct drug effect or reduction of EPS[J].Schizophr Res, 2000, 46(1):81-89.
[11] 朱培俊, 陈志恩, 张静, 等.阿立哌唑治疗精神分裂症的临床评价[J].中国临床药理学与治疗学, 2005, 10(10):978-980.
[12] Stip E, Chouinard S, Boulay LJ.On the trail of a cognitive enhancer for the treatment of schizophrenia[J].Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(3):219-232.
[13] 宋明柯, 胡国渊, 陈红专.M 胆碱受体调控的M 通道 — 神经精神药物的新靶点[J].中国临床药理学与治疗学, 2006, 11(11):1219-1224

[1]	李娜, 韩鸿璨, 王骏. 以药动学方法评价的抗精神分裂症药物人体生物等效性研究的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(12): 1419-1425.
[2]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[3]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[4]	胡德凤，王轶虎，龙小宇，王广水. 甘麦大枣汤加减方联合认知行为干预对精神分裂症超高危人群的干预作用及对认知功能、生活质量及血清5-HT、MT、TSH水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 546-553.
[5]	樊垚，薛永，汪昕，陈雪菲，张旭，姚应水，沈冲. 载脂蛋白E基因多态性与利培酮所致体质量降低的关联研究[J]. 中国临床药理学与治疗学, 2019, 24(3): 288-295.
[6]	曹婷，李娜娜，蔡骅琳. 神经甾体在精神分裂症发病与治疗中作用的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(6): 709-714.
[7]	崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.
[8]	周勇，陈雪芳，黄汉津. 氨磺必利治疗精神分裂症疗效以及安全性研究[J]. 中国临床药理学与治疗学, 2017, 22(10): 1152-1157.
[9]	陶怀, 魏钦令, 杨佳锦, 刘勇, 唐姝娟. 不同剂量帕潘立酮治疗对精神分裂症发育模型大鼠行为学的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 1001-1006.
[10]	杨艳，夏泳，朱长江，陈艳波. 阿立哌唑对氨磺必利所致高泌乳素血症的影响研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 693-696.
[11]	郑付春, 陈高勇, 李振鹏, 李伟秋, 郑燕珊, 徐涵, 石刚刚, 张艳美. 钙拮抗剂通过PKCα/ERK1/2通路拮抗心肌细胞缺氧复氧损伤[J]. 中国临床药理学与治疗学, 2015, 20(8): 865-870.
[12]	杭荣华, 李业平, 吴明飞, 李瑞. 门诊精神分裂症患者药物治疗的依从性与不良反应、社会支持的关系[J]. 中国临床药理学与治疗学, 2014, 19(8): 912-915.
[13]	倪平, 吕海龙, 国效峰, 张丽丽, 许林勇. 利培酮与奥氮平对精神分裂症急性期的疗效及临床影响因素的比较[J]. 中国临床药理学与治疗学, 2014, 19(2): 182-185.
[14]	任志斌, 陈正昕, 金卫东, 马永春, 陈炯, 邢葆平, 王鹤秋. 齐拉西酮联合心境稳定剂治疗双相障碍躁狂发作和混合发作[J]. 中国临床药理学与治疗学, 2013, 18(1): 78-82.
[15]	唐亚梅, 张向晖, 刘勇. 地佐环平诱导的精神分裂症发育模型大鼠脑组织去甲肾上腺素、5-羟色胺及代谢产物的浓度变化[J]. 中国临床药理学与治疗学, 2012, 17(7): 721-726.